226 related articles for article (PubMed ID: 29617843)
1. In vivo evaluation of EGFRvIII mutation in primary glioblastoma patients via complex multiparametric MRI signature.
Akbari H; Bakas S; Pisapia JM; Nasrallah MP; Rozycki M; Martinez-Lage M; Morrissette JJD; Dahmane N; O'Rourke DM; Davatzikos C
Neuro Oncol; 2018 Jul; 20(8):1068-1079. PubMed ID: 29617843
[TBL] [Abstract][Full Text] [Related]
2.
Bakas S; Akbari H; Pisapia J; Martinez-Lage M; Rozycki M; Rathore S; Dahmane N; O'Rourke DM; Davatzikos C
Clin Cancer Res; 2017 Aug; 23(16):4724-4734. PubMed ID: 28428190
[No Abstract] [Full Text] [Related]
3. Detection of wild-type EGFR amplification and EGFRvIII mutation in CSF-derived extracellular vesicles of glioblastoma patients.
Figueroa JM; Skog J; Akers J; Li H; Komotar R; Jensen R; Ringel F; Yang I; Kalkanis S; Thompson R; LoGuidice L; Berghoff E; Parsa A; Liau L; Curry W; Cahill D; Bettegowda C; Lang FF; Chiocca EA; Henson J; Kim R; Breakefield X; Chen C; Messer K; Hochberg F; Carter BS
Neuro Oncol; 2017 Oct; 19(11):1494-1502. PubMed ID: 28453784
[TBL] [Abstract][Full Text] [Related]
4. Use of magnetic perfusion-weighted imaging to determine epidermal growth factor receptor variant III expression in glioblastoma.
Tykocinski ES; Grant RA; Kapoor GS; Krejza J; Bohman LE; Gocke TA; Chawla S; Halpern CH; Lopinto J; Melhem ER; O'Rourke DM
Neuro Oncol; 2012 May; 14(5):613-23. PubMed ID: 22492960
[TBL] [Abstract][Full Text] [Related]
5. Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens.
Feldkamp MM; Lala P; Lau N; Roncari L; Guha A
Neurosurgery; 1999 Dec; 45(6):1442-53. PubMed ID: 10598712
[TBL] [Abstract][Full Text] [Related]
6. Radiomic subtyping improves disease stratification beyond key molecular, clinical, and standard imaging characteristics in patients with glioblastoma.
Kickingereder P; Neuberger U; Bonekamp D; Piechotta PL; Götz M; Wick A; Sill M; Kratz A; Shinohara RT; Jones DTW; Radbruch A; Muschelli J; Unterberg A; Debus J; Schlemmer HP; Herold-Mende C; Pfister S; von Deimling A; Wick W; Capper D; Maier-Hein KH; Bendszus M
Neuro Oncol; 2018 May; 20(6):848-857. PubMed ID: 29036412
[TBL] [Abstract][Full Text] [Related]
7. Mapping of genomic EGFRvIII deletions in glioblastoma: insight into rearrangement mechanisms and biomarker development.
Koga T; Li B; Figueroa JM; Ren B; Chen CC; Carter BS; Furnari FB
Neuro Oncol; 2018 Sep; 20(10):1310-1320. PubMed ID: 29660021
[TBL] [Abstract][Full Text] [Related]
8. Radiolabeled novel mAb 4G1 for immunoSPECT imaging of EGFRvIII expression in preclinical glioblastoma xenografts.
Liu X; Dong C; Shi J; Ma T; Jin Z; Jia B; Liu Z; Shen L; Wang F
Oncotarget; 2017 Jan; 8(4):6364-6375. PubMed ID: 28031526
[TBL] [Abstract][Full Text] [Related]
9. Histopathology-validated machine learning radiographic biomarker for noninvasive discrimination between true progression and pseudo-progression in glioblastoma.
Akbari H; Rathore S; Bakas S; Nasrallah MP; Shukla G; Mamourian E; Rozycki M; Bagley SJ; Rudie JD; Flanders AE; Dicker AP; Desai AS; O'Rourke DM; Brem S; Lustig R; Mohan S; Wolf RL; Bilello M; Martinez-Lage M; Davatzikos C
Cancer; 2020 Jun; 126(11):2625-2636. PubMed ID: 32129893
[TBL] [Abstract][Full Text] [Related]
10. Epidermal Growth Factor Receptor Variant III (EGFRvIII) Positivity in
Felsberg J; Hentschel B; Kaulich K; Gramatzki D; Zacher A; Malzkorn B; Kamp M; Sabel M; Simon M; Westphal M; Schackert G; Tonn JC; Pietsch T; von Deimling A; Loeffler M; Reifenberger G; Weller M;
Clin Cancer Res; 2017 Nov; 23(22):6846-6855. PubMed ID: 28855349
[No Abstract] [Full Text] [Related]
11. Potential role of preoperative conventional MRI including diffusion measurements in assessing epidermal growth factor receptor gene amplification status in patients with glioblastoma.
Young RJ; Gupta A; Shah AD; Graber JJ; Schweitzer AD; Prager A; Shi W; Zhang Z; Huse J; Omuro AM
AJNR Am J Neuroradiol; 2013 Dec; 34(12):2271-7. PubMed ID: 23811973
[TBL] [Abstract][Full Text] [Related]
12. Radiomic MRI signature reveals three distinct subtypes of glioblastoma with different clinical and molecular characteristics, offering prognostic value beyond IDH1.
Rathore S; Akbari H; Rozycki M; Abdullah KG; Nasrallah MP; Binder ZA; Davuluri RV; Lustig RA; Dahmane N; Bilello M; O'Rourke DM; Davatzikos C
Sci Rep; 2018 Mar; 8(1):5087. PubMed ID: 29572492
[TBL] [Abstract][Full Text] [Related]
13. Imaging Surrogates of Infiltration Obtained Via Multiparametric Imaging Pattern Analysis Predict Subsequent Location of Recurrence of Glioblastoma.
Akbari H; Macyszyn L; Da X; Bilello M; Wolf RL; Martinez-Lage M; Biros G; Alonso-Basanta M; OʼRourke DM; Davatzikos C
Neurosurgery; 2016 Apr; 78(4):572-80. PubMed ID: 26813856
[TBL] [Abstract][Full Text] [Related]
14. Prediction of IDH1 Mutation Status in Glioblastoma Using Machine Learning Technique Based on Quantitative Radiomic Data.
Lee MH; Kim J; Kim ST; Shin HM; You HJ; Choi JW; Seol HJ; Nam DH; Lee JI; Kong DS
World Neurosurg; 2019 May; 125():e688-e696. PubMed ID: 30735871
[TBL] [Abstract][Full Text] [Related]
15. The epidermal growth factor receptor variant type III mutation frequently found in gliomas induces astrogenesis in human cerebral organoids.
Kim HM; Lee SH; Lim J; Yoo J; Hwang DY
Cell Prolif; 2021 Feb; 54(2):e12965. PubMed ID: 33283409
[TBL] [Abstract][Full Text] [Related]
16. Radiogenomic analysis of PTEN mutation in glioblastoma using preoperative multi-parametric magnetic resonance imaging.
Li Y; Liang Y; Sun Z; Xu K; Fan X; Li S; Zhang Z; Jiang T; Liu X; Wang Y
Neuroradiology; 2019 Nov; 61(11):1229-1237. PubMed ID: 31218383
[TBL] [Abstract][Full Text] [Related]
17. EGFRvIII mutations can emerge as late and heterogenous events in glioblastoma development and promote angiogenesis through Src activation.
Eskilsson E; Rosland GV; Talasila KM; Knappskog S; Keunen O; Sottoriva A; Foerster S; Solecki G; Taxt T; Jirik R; Fritah S; Harter PN; Välk K; Al Hossain J; Joseph JV; Jahedi R; Saed HS; Piccirillo SG; Spiteri I; Leiss L; Euskirchen P; Graziani G; Daubon T; Lund-Johansen M; Enger PØ; Winkler F; Ritter CA; Niclou SP; Watts C; Bjerkvig R; Miletic H
Neuro Oncol; 2016 Dec; 18(12):1644-1655. PubMed ID: 27286795
[TBL] [Abstract][Full Text] [Related]
18. Pretreatment Dynamic Susceptibility Contrast MRI Perfusion in Glioblastoma: Prediction of EGFR Gene Amplification.
Gupta A; Young RJ; Shah AD; Schweitzer AD; Graber JJ; Shi W; Zhang Z; Huse J; Omuro AM
Clin Neuroradiol; 2015 Jun; 25(2):143-50. PubMed ID: 24474262
[TBL] [Abstract][Full Text] [Related]
19. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial.
Weller M; Butowski N; Tran DD; Recht LD; Lim M; Hirte H; Ashby L; Mechtler L; Goldlust SA; Iwamoto F; Drappatz J; O'Rourke DM; Wong M; Hamilton MG; Finocchiaro G; Perry J; Wick W; Green J; He Y; Turner CD; Yellin MJ; Keler T; Davis TA; Stupp R; Sampson JH;
Lancet Oncol; 2017 Oct; 18(10):1373-1385. PubMed ID: 28844499
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of epidermal growth factor receptor amplification and EGFRvIII in glioblastoma: meta-analysis.
Chen JR; Xu HZ; Yao Y; Qin ZY
Acta Neurol Scand; 2015 Nov; 132(5):310-22. PubMed ID: 25846813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
